Float Short %

7.31

Margin Of Safety %

Put/Call OI Ratio

0.01

EPS Next Q Diff

0.09

EPS Last/This Y

12.23

EPS This/Next Y

0.84

Price

2.86

Target Price

19.4

Analyst Recom

Performance Q

-33.02

Relative Volume

0.46

Beta

0.25

Ticker: XAIR

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-04	XAIR	0.179	0.01	0.31	7820
2025-07-07	XAIR	0.1899	0.01	0.06	7846
2025-07-08	XAIR	0.208	0.01	0.01	8078
2025-07-09	XAIR	0.2051	0.01	0.03	8550
2025-07-10	XAIR	0.1951	0.01	0.15	8597
2025-07-11	XAIR	0.1707	0.01	0.05	8609
2025-07-14	XAIR	3.035	0.01	0.00	8679
2025-07-15	XAIR	3.16	0.01	0.00	8679
2025-07-16	XAIR	3.24	0.01	0.00	8679
2025-07-17	XAIR	3.26	0.01	0.50	8571
2025-07-18	XAIR	3.26	0.01	0.00	8570
2025-07-21	XAIR	3.28	0.01	0.00	4196
2025-07-22	XAIR	3.38	0.01	0.00	4204
2025-07-23	XAIR	3.38	0.01	0.00	4204
2025-07-24	XAIR	3.31	0.01	0.00	4205
2025-07-25	XAIR	3.17	0.01	0.00	4203
2025-07-28	XAIR	3.1906	0.01	0.00	4200
2025-07-29	XAIR	3.02	0.01	0.00	4200
2025-07-30	XAIR	3.02	0.01	0.00	4200
2025-07-31	XAIR	2.97	0.01	0.00	4200
2025-08-01	XAIR	2.8259	0.01	0.00	4200
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-04	XAIR	0.18	-	-	0.00
2025-07-07	XAIR	0.19	-	-	0.00
2025-07-08	XAIR	0.21	-	-	0.00
2025-07-09	XAIR	0.21	-	-	0.00
2025-07-10	XAIR	0.19	-	-	0.00
2025-07-11	XAIR	0.17	-	-	0.00
2025-07-14	XAIR	3.05	-	-	0.00
2025-07-15	XAIR	3.16	-	-	0.00
2025-07-16	XAIR	3.24	-	-	0.00
2025-07-17	XAIR	3.24	-	-	0.00
2025-07-18	XAIR	3.26	-	-	0.00
2025-07-21	XAIR	3.30	-	-	0.00
2025-07-22	XAIR	3.35	-	-	0.00
2025-07-23	XAIR	3.36	-	-	0.00
2025-07-24	XAIR	3.32	-	-	0.00
2025-07-25	XAIR	3.20	-	-	-1.57
2025-07-28	XAIR	3.19	-	-	-1.57
2025-07-29	XAIR	2.96	-	-	-1.57
2025-07-30	XAIR	3.01	-	-	-1.57
2025-07-31	XAIR	2.98	-	-	-1.57
2025-08-01	XAIR	2.86	-	-	-1.57
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-04	XAIR	9.19	25.23	4.26
2025-07-07	XAIR	9.19	25.23	4.26
2025-07-08	XAIR	9.19	25.23	4.26
2025-07-09	XAIR	9.19	25.23	4.26
2025-07-10	XAIR	9.19	25.23	4.26
2025-07-11	XAIR	9.19	25.23	7.72
2025-07-14	XAIR	9.19	25.23	7.72
2025-07-15	XAIR	168.30	25.23	7.72
2025-07-16	XAIR	168.30	25.23	7.72
2025-07-17	XAIR	167.71	25.23	7.72
2025-07-18	XAIR	167.72	25.23	7.72
2025-07-21	XAIR	167.64	0	7.72
2025-07-22	XAIR	167.64	0	7.72
2025-07-23	XAIR	168.64	0	7.72
2025-07-24	XAIR	168.64	0	7.72
2025-07-25	XAIR	168.68	0	7.31
2025-07-28	XAIR	168.66	0	7.31
2025-07-29	XAIR	168.27	0	7.31
2025-07-30	XAIR	168.27	0	7.31
2025-07-31	XAIR	168.34	0	7.31
2025-08-01	XAIR	168.25	0	7.31
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.09

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

168.25

Institutional Transactions

Beta

0.25

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

98.2

Max Drawdown 5-Year %

Target Price

19.4

P/E

Forward P/E

PEG

P/S

3.58

P/B

0.87

P/Free Cash Flow

EPS

-15.73

Average EPS Est. Cur. Y

-1.57

EPS Next Y. (Est.)

-0.73

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1258.46

Relative Volume

0.46

Return on Equity vs Sector %

-367

Return on Equity vs Industry %

-361.5

EPS 1 7Days Diff

-1.6

EPS 1 30Days Diff

-1.57

EBIT Estimation

Beyond Air, Inc.

Sector: Healthcare

Industry: Medical Devices

Employees: 61

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

stock quote shares XAIR – Beyond Air Inc Stock Price stock today

news today XAIR – Beyond Air Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch XAIR – Beyond Air Inc yahoo finance google finance

stock history XAIR – Beyond Air Inc invest stock market

stock prices XAIR premarket after hours

ticker XAIR fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: XAIR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y